Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer

2017 ◽  
Vol 24 (3) ◽  
pp. 560-568 ◽  
Author(s):  
Giovanna Rossi ◽  
Zhaomei Mu ◽  
Alfred W. Rademaker ◽  
Laura K. Austin ◽  
Kimberly S. Strickland ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Liquid Biopsy ◽  
Advanced Breast ◽  
Cell Free Dna ◽  
Free Dna

Detection of circulating tumor cells in patients with advanced breast cancer according to the immunohistochemical subtype.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e21022-e21022
Author(s):  
D. Peeters ◽  
P. van Dam ◽  
G. Van den Eynden ◽  
I. Benoy ◽  
S. J. Van Laere ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Advanced Breast

The DETECT Study Program: Personalized treatment in advanced breast cancer based on circulating tumor cells (CTCs).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. TPS11109-TPS11109
Author(s):  
Amelie Schramm ◽  
Thomas W. P. Friedl ◽  
Susanne Albrecht ◽  
Jens Bodo Huober ◽  
Brigitte Kathrin Rack ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Advanced Breast ◽  
Personalized Treatment ◽  
Study Program

Changes of HER2 Status in Circulating Tumor Cells Compared With the Primary Tumor During Treatment for Advanced Breast Cancer

2010 ◽  
Vol 10 (5) ◽  
pp. 392-397 ◽  
Author(s):  
Elisabetta Munzone ◽  
Franco Nolé ◽  
Aron Goldhirsch ◽  
Edoardo Botteri ◽  
Angela Esposito ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Primary Tumor ◽  
Advanced Breast ◽  
Her2 Status

scholarly journals Multimodal Targeted Deep Sequencing of Circulating Tumor Cells and Matched Cell-Free DNA Provides a More Comprehensive Tool to Identify Therapeutic Targets in Metastatic Breast Cancer Patients

Cancers ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1084 ◽  
Author(s):  
Corinna Keup ◽  
Markus Storbeck ◽  
Siegfried Hauch ◽  
Peter Hahn ◽  
Markus Sprenger-Haussels ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Cell Free Dna ◽  
Free Dna

Cell-free DNA (cfDNA) and circulating tumor cells (CTCs) exhibit great potential for therapy management in oncology. We aimed to establish a multimodal liquid biopsy strategy that is usable with minimized blood volume to deconvolute the genomic complexity of metastatic breast cancer. CTCs were isolated from 10ml blood of 18 hormone receptor-positive and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer patients. cfDNA was isolated from plasma generated after CTC depletion and targeted sequencing analyses were conducted. PIK3CA and ESR1 variants were less common in CTC gDNA, while ERBB2 variants were only detected in CTC gDNA. A total of 62% of all cfDNA variants were recovered in the matched CTC gDNA, while 72% of all variants were unique in either cfDNA (14 variants) or CTC gDNA (104 variants). The percentage of patients with no detectable cfDNA variants or CTC gDNA variants was 17%/11%, but a combined analysis identified variants in 94% of all patients. In univariate and multivariate regression models, ESR1 variants in cfDNA and CTC gDNA correlated significantly with survival. We suggest a coordinated analysis of both fractions in order to provide a comprehensive genomic footprint that may contribute to identifying the most suitable therapy for each individual.

Sign in / Sign up

Export Citation Format

Share Document